Answers are grounded in this paper and cite their sources.
T-VEC is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clinical trial. T-VEC was well tolerated and resulted in a higher DRR (P < .001) and longer median OS (P = .051), particularly in untreated patients or those with stage IIIB, IIIC, or IVM1a disease. T-VEC represents a novel potential therapy for patients with metastatic melanoma.
No takes yet. Share an insight, caveat, or question.
Andtbacka et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: